IMRIS receives FDA clearance for IMRISnv and IMRIScardio

WINNIPEG, Sept. 8 /PRNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced that it has received
510(k) clearance from the US Food and Drug Administration (FDA), permitting the Company to market its newest products, IMRISNV and IMRIScardio in the United States.

IMRISNV and IMRIScardio are the first systems in the world to allow the capabilities of both MRI and x-ray angiography in a single suite without theneed to transport the patient between modalities.

Neurovascular diseases including acute ischemic stroke require rapid assessment and treatment. IMRISNV features a wide bore 3T MRI scanner and a bi-plane angiography system completely integrated into a single suite that permits the patient to transition quickly and seamlessly between MR imaging and intervention without transporting the patient between modalities. Using IMRISNV, MR images can be
taken before and during procedures to assess tissue health, and can also be used in conjunction with the fluoroscopic images during the interventional procedure. On completion of the procedure, new images can be taken to evaluate the intervention.


source: IMRIS